L. Puig

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Epidemiology of atopic dermatitis in adults: Results from an international survey

S. Barbarot, S. Auziere, A. Gadkari et al. · Allergy · 2018 · 849 citations · Full text

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 790 citations · Full text

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Iain B. McInnes, Arthur Kavanaugh, Alice B. Gottlieb et al. · The Lancet · 2013 · 789 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +11

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Christopher T. Ritchlin, Proton Rahman, Arthur Kavanaugh et al. · Annals of the Rheumatic Diseases · 2014 · 654 citations · Full text